ArticleHNO2025
[The microbiome in diseases of the nose and paranasal sinuses].
Article in HNO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeted Next-Generation Sequencing Analysis of BALF Microbiota and Clinical Characteristics in Severe versus Non-Severe Community-Acquired Pneumonia.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nasal microbiome refers to the composition and diversity of bacterial communities residing in the nasal cavity. While the gut microbiome has been the primary focus of microbiome research in recent years, driven by advances in diagnostic technologies, increasing attention is now being directed toward microbial ecosystems in other regions of the body, including the respiratory tract. In general, a high and stable microbial diversity (α-diversity) is considered indicative of a "healthy" microbial community. Conversely, reduced bacterial diversity has been associated with clinical conditions, such as chronic rhinosinusitis (CRS); however, it remains unclear whether such microbial alterations are a cause or consequence of the disease, as current evidence does not yet allow for definitive conclusions. Interpreting existing studies on the nasal microbiome is challenging due to several factors: the low microbial biomass in the nasal cavity, the technical difficulty of accurately analyzing such samples, and the lack of standardized methodologies for sampling and data interpretation. These limitations contribute to the heterogeneity of current findings and highlight the need for consistent, guideline-based research protocols in this emerging field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.